文献速递生殖医学

高收入国家辅助生殖技术干预的经济学评价:系统综述

Economic evaluations of assisted reproductive technologies in high-income countries: a systematic review.
PubMed 文献 · Hum Reprod · 2024-01-01

本系统综述检索7个数据库,纳入2011年1月至2022年6月发表的40项在高收入国家开展的辅助生殖技术(ART)经济学评价研究。多数高成本干预(如全人群胚胎植入前非整倍体遗传学检测(PGT-A)和不明原因不孕的卵胞浆内单精子注射(ICSI))因效果提升有限或无效而不太可能具有成本效果。

要点

  • 多数高成本ART干预(如全人群PGT-A、不明原因不孕的ICSI)因效果提升有限或无效而不太可能具有成本效果。
  • 使用生物类似药或HMG进行卵巢刺激费用更低但会降低临床有效性。
  • 纳入研究缺乏基于偏好的标准化结局,且部分干预的疗效证据并非基于高质量随机试验。

核心结论

  • 在所有被评估的ART干预中,大多数高成本干预(包括全人群的PGT-A和不明原因不孕的ICSI)因效果提升有限或无效而不太可能具有成本效果。

研究设计与样本

  • 系统综述,检索MEDLINE、PUBMED、EMBASE、COCHRANE、ECONLIT、SCOPUS和CINAHL共7个数据库,纳入2011年1月以来发表的高收入国家ART干预经济学评价研究,最后检索日期为2022年6月22日。
  • 共纳入40项研究,在高收入国家开展,其中34项为成本效果分析。
  • 由两名独立评审者评估文献并纳入符合标准的研究,采用CHEERS标准评估报告完整性。

主要发现

  • 纳入研究来自11个高收入国家,ART干预包括控制性卵巢刺激药物或策略(n=15)、IVF(n=9)、PGT-A(n=7)、单胚胎移植(n=5)、ICSI(n=3)和全胚冷冻移植(n=1)。
  • 活产是最常报告的主要结局(n=27),3项研究报告了质量调整生命年。
  • 85%(n=34)的研究采用卫生资助者视角,没有研究测量患者对治疗的偏好。
  • PGT-A是否较未使用PGT-A的IVF周期提高妊娠率仍不确定,因此无法证明其成本效果;非男性因素不孕的ICSI与标准IVF受精相比似乎无临床有效性,因此不具有成本效果。
  • 使用生物类似药或HMG进行卵巢刺激费用更低但会降低临床有效性。

关键数值与推荐

  • PGT-A与未使用PGT-A的IVF周期相比,妊娠率是否提高仍不确定,无法证明成本效果。
  • 非男性因素不孕的ICSI与标准IVF受精相比似乎无临床有效性,因此不具有成本效果。
  • 使用生物类似药或HMG进行卵巢刺激费用更低但会降低临床有效性。

临床怎么用

  • 本系统综述或可帮助ART资助者决定如何最优投资以最大化获得健康孩子的可能性。
  • 作者认为在个人和群体层面投资于帮助使用ART的不孕人群的策略是合理的(原文为justifiable)。
  • 原文未据此给出具体临床推荐。

局限性

  • 缺乏基于偏好的和标准化的结局限制了研究间结果的可比性。
  • 部分干预用于经济学评价的疗效证据并非总是基于高质量随机试验和系统综述。
  • 对个体和国家资助者治疗不孕的支付意愿阈值了解不足。
  • 报告质量评分存在差异,可能增加成本效果结果的不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Which assited reproductive technology (ART) interventions in high-income countries are cost-effective and which are not? SUMMARY ANSWER: Among all ART interventions assessed in economic evaluations, most high-cost interventions, including preimplantation genetic testing for aneuploidy (PGT-A) for a general population and ICSI for unexplained infertility, are unlikely to be cost-effective owing to minimal or no increase in effectiveness. WHAT IS KNOWN ALREADY: Approaches to reduce costs in order to increase access have been identified as a research priority for future infertility research. There has been an increasing number of ART interventions implemented in routine clinical practice globally, before robust assessments of evidence on economic evaluations. The extent of clinical effectiveness of some studied comparisons has been evaluated in high-quality research, allowing more informative decision making around cost-effectiveness. STUDY DESIGN, SIZE, DURATION: We performed a systematic review and searched seven databases (MEDLINE, PUBMED, EMBASE, COCHRANE, ECONLIT, SCOPUS, and CINAHL) for studies examining ART interventions for infertility together with an economic evaluation component (cost-effectiveness, cost-benefit, cost-utility, or cost-minimization assessment), in high-income countries, published since January 2011. The last search was 22 June 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS: Two independent reviewers assessed publications and included those fulfilling the eligibility criteria. Studies were examined to assess the cost-effectiveness of the studied intervention, as well as the reporting quality of the study. The chosen outcome measure and payer perspective were also noted. Completeness of reporting was assessed against the Consolidated Health Economic Evaluation Reporting Standard. Results are presented and summarized based on the intervention studied. MAIN RESULTS AND THE ROLE OF CHANCE: The review included 40 studies which were conducted in 11 high-income countries. Most studies (n = 34) included a cost-effectiveness analysis. ART interventions included medication or strategies for controlled ovarian stimulation (n = 15), IVF (n = 9), PGT-A (n = 7), single embryo transfer (n = 5), ICSI (n = 3), and freeze-all embryo transfer (n = 1). Live birth was the mostly commonly reported primary outcome (n = 27), and quality-adjusted life years was reported in three studies. The health funder perspective was used in 85% (n = 34) of studies. None of the included studies measured patient preference for treatment. It remains uncertain whether PGT-A improves pregnancy rates compared to IVF cycles managed without PGT-A, and therefore cost-effectiveness could not be demonstrated for this intervention. Similarly, ICSI in non-male factor infertility appears not to be clinically effective compared to standard fertilization in an IVF cycle and is therefore not cost-effective. Interventions such as use of biosimilars or HMG for ovarian stimulation are cheaper but compromise clinical effectiveness. LIMITATIONS, REASONS FOR CAUTION: Lack of both preference-based and standardized outcomes limits the comparability of results across studies. The selection of efficacy evidence offered for some interventions for economic evaluations is not always based on high-quality randomized trials and systematic reviews. In addition, there is insufficient knowledge of the willingness to pay thresholds of individuals and state funders for treatment of infertility. There is variable quality of reporting scores, which might increase uncertainty around the cost-effectiveness results. WIDER IMPLICATIONS OF THE FINDINGS: Investment in strategies to help infertile people who utilize ART is justifiable at both personal and population levels. This systematic review may assist ART funders decide how to best invest to maximize the likelihood of delivery of a healthy child. STUDY FUNDING/COMPETING INTEREST(S): There was no funding for this study. E.C. and R.W. receive salary support from the National Health and Medical Research Council (NHMRC) through their fellowship scheme (EC GNT1159536, RW 2021/GNT2009767). M.D.-T. reports consulting fees from King Fahad Medical School. All other authors have no competing interests to declare. REGISTRATION NUMBER: Prospero CRD42021261537.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Olive E, Bull C, Gordon A, et al. Economic evaluations of assisted reproductive technologies in high-income countries: a systematic review. Hum Reprod. 2024. PMID: 38438132. doi:10.1093/humrep/deae039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。